Last reviewed · How we verify
Pazopanib+Sorafenib
This combination of two tyrosine kinase inhibitors blocks multiple receptor pathways (VEGFR, PDGFR, RAF kinase) to inhibit tumor angiogenesis and cell proliferation.
This combination of two tyrosine kinase inhibitors blocks multiple receptor pathways (VEGFR, PDGFR, RAF kinase) to inhibit tumor angiogenesis and cell proliferation. Used for Advanced or metastatic renal cell carcinoma, Other solid tumors (under investigation in phase 3).
At a glance
| Generic name | Pazopanib+Sorafenib |
|---|---|
| Sponsor | Technical University of Munich |
| Drug class | Multi-targeted tyrosine kinase inhibitor combination |
| Target | VEGFR, PDGFR, RAF kinase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pazopanib and sorafenib are both multi-targeted receptor tyrosine kinase inhibitors that suppress vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and RAF kinase signaling. By combining these agents, the regimen aims to achieve broader kinase inhibition and potentially overcome resistance mechanisms in cancer cells. This dual approach targets both tumor vasculature and intrinsic oncogenic pathways.
Approved indications
- Advanced or metastatic renal cell carcinoma
- Other solid tumors (under investigation in phase 3)
Common side effects
- Diarrhea
- Hypertension
- Hand-foot skin reaction
- Fatigue
- Nausea
- Hepatotoxicity
Key clinical trials
- Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (PHASE2)
- TDM for Optimized Outcome in Patients With mRCC.
- A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
- Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer (PHASE2)
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pazopanib+Sorafenib CI brief — competitive landscape report
- Pazopanib+Sorafenib updates RSS · CI watch RSS
- Technical University of Munich portfolio CI